☆ 4.7 Article

Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma

ONCOLOGIST (2022)

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment

Changhee Park et al.

Summary: Angiosarcoma is a highly aggressive mesenchymal tumor for which systemic chemotherapy is often considered, but the outcomes of such treatment are unsatisfactory. First-line weekly paclitaxel and later-line pazopanib monotherapy may provide survival benefit, especially for advanced angiosarcoma patients without liver involvement.

CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Article Oncology

Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma

Sandra P. D'Angelo et al.

ONCOLOGY (2015)

添加到收藏夹

Article Oncology

First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

R. J. Young et al.

EUROPEAN JOURNAL OF CANCER (2014)

添加到收藏夹

Article Oncology

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

Nicolas Penel et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma

相关参考文献

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment

Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma

First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

导出引文

分享论文